Biomimesys is providing a great opportunity to culture human induced pluripotent stem cells (hiPSCs) in 3D and differentiate them into different kind of cell types including liver cells. Showcased by Méryl Roudaut at the 20th International Congress on In Vitro Toxicology (ESTIV2018), our co-development with the institute du thorax (U1087) of Nantes and the RHU CHOPIN is moving forward.

Karim Si-Tayeb, who is leading the project from Nantes, had the opportunity to present our new development on hiPSC-derived liver organoïds functionalities in Biomimesys at two important events from this end of the year.

First, liver organoids characterization including staining for hepatocytes, quiescent stellate cells, activated stellate cells, organoid’s abilities to store lipids upon amiodarone or ethanol treatments were presented at the 3rd meeting of the French Society for Stem Cell Research (FSSCR) in Lyon. Then a poster followed by a lot of fruitful discussions, was presented during the symposium “From 3D Culture to Organoid” co-organized in Paris by the ITMO Health Technologies and the ITMO Cell Biology, Development and Evolution.

Stay tune for our next developments with a quiet disruptive model!!


Grégory MAUBON

Grégory MAUBON is Chief Data Officer and digital coordinator at HCS Pharma, a biotech startup focused in high content screening and complex diseases. He manages IT missions and leads digital usages linked to company needs. He is also a Augmented Reality Evangelist (presenter and lecturer) since 2008, where he created www.augmented-reality.fr and founded in 2010 RA'pro (the augmented reality promotion association). He helped many companies (in several domains) to define precisely their augmented reality needs and supported them in the implementation.

0 Comments

Leave a Reply